Review
Biochemistry & Molecular Biology
Vishal Khatri, Ramaswamy Kalyanasundaram
Summary: This review focuses on the association between IBD and gut inflammasome, as well as recent advances in research and therapeutic strategies for IBD, discussing inflammasomes and their components, outcomes from experimental animals and human studies, inflammasome inhibitors, and developments in inflammasome-targeted therapies for IBD.
Review
Biochemistry & Molecular Biology
HyunTaek Jung, Jae Seok Kim, Keum Hwa Lee, Kalthoum Tizaoui, Salvatore Terrazzino, Sarah Cargnin, Lee Smith, Ai Koyanagi, Louis Jacob, Han Li, Sung Hwi Hong, Dong Keon Yon, Seung Won Lee, Min Seo Kim, Paul Wasuwanich, Wikrom Karnsakul, Jae Il Shin, Andreas Kronbichler
Summary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract that mainly affects young people. Recent studies have shown that microRNAs (miRNAs) play an important role in the pathogenesis, diagnosis, and treatment of IBD.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Medicine, General & Internal
Silvia Salvatori, Francesco Baldassarre, Michelangela Mossa, Giovanni Monteleone
Summary: Long COVID is common in patients with inflammatory bowel diseases (IBD), with fatigue being the most frequent symptom. It does not influence the frequency of IBD relapses, but is more prevalent in female patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Thomas M. Goodsall, Tran M. Nguyen, Claire E. Parker, Christopher Ma, Jane M. Andrews, Vipul Jairath, Robert Bryant
Summary: The study systematically identified ultrasound scoring indices for assessing inflammatory bowel disease activity, with common components including bowel wall thickness, colour Doppler imaging, and bowel wall stratification. The correlation between ultrasound indices and reference standards, as well as sensitivity, specificity, accuracy, and other properties, varied within certain ranges. However, reliability and responsiveness data were limited, and most studies were rated with unclear or high risk of bias.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Medicine, General & Internal
Katarzyna Akutko, Andrzej Stawarski
Summary: Inflammatory bowel diseases (IBD) are chronic inflammatory diseases of the digestive tract with periods of remission and relapses. The etiopathogenesis is not fully understood, leading to only symptomatic treatment. There is a constant need to search for new high safety profile therapies for IBD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Shirley Cohen-Mekelburg, Xianshi Yu, Deena Costa, Timothy P. Hofer, Sarah Krein, John Hollingsworth, Wyndy Wiitala, Sameer Saini, Ji Zhu, Akbar Waljee
Summary: A national study showed evidence of variability in patient-sharing among IBD care teams, with patients at health centers with higher provider connectedness having better outcomes. Understanding provider connectedness is a step towards developing network-based interventions to enhance coordination and quality of care.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Laila Aldars-Garcia, Alicia C. Marin, Maria Chaparro, Javier P. Gisbert
Summary: The gut microbiota plays a crucial role in human health, contributing to the development of the immune system, digestion, metabolism, and barrier against pathogens. Inflammatory bowel disease (IBD) is characterized by an exaggerated immune reaction against intestinal microbiota, with changes in abundance of specific microorganisms associated with the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biotechnology & Applied Microbiology
Guihua Chen, Jun Shen
Summary: Inflammatory bowel disease (IBD) is a global disease with high morbidity and medical costs. Early diagnosis and intervention are crucial for controlling its progression.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
Editorial Material
Gastroenterology & Hepatology
Catherine Le Berre, Laurent Peyrin-Biroulet
Summary: The SPIRIT consensus group has agreed that the ultimate therapeutic goal in both CD and UC is to prevent disease impact on patients' lives, including health-related quality of life, disability, and fecal incontinence, as well as prevent complications in the short and long term, such as bowel damage, surgeries, disease extension, extraintestinal manifestations, and dysplasia or cancer. These recommendations will need to be validated in clinical studies before being implemented in disease-modification trials.
Article
Multidisciplinary Sciences
Ryan W. Gan, Diana Sun, Amanda R. Tatro, Shirley Cohen-Mekelburg, Wyndy L. Wiitala, Ji Zhu, Akbar K. Waljee
Summary: This study replicated a machine-learning model's ability to predict acute exacerbations of inflammatory bowel disease (IBD) in a nationally representative cohort, with the random forest model outperforming the logistic regression model.
Review
Medicine, General & Internal
Elisabetta Antonelli, Gabrio Bassotti, Marta Tramontana, Katharina Hansel, Luca Stingeni, Sandro Ardizzone, Giovanni Genovese, Angelo Valerio Marzano, Giovanni Maconi
Summary: This review summarizes the dermatologic manifestations occurring in patients with inflammatory bowel diseases, including specific manifestations, cutaneous disorders associated with IBDs, reactive mucocutaneous manifestations of IBDs, mucocutaneous conditions secondary to treatment, and manifestations due to nutritional malabsorption. An accurate dermatological examination is crucial in all IBD patients, especially in candidates to biologic therapies where drug-induced cutaneous reactions may be clinically relevant.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Anastasia Katsoula, Georgios Axiaris, Afroditi Mpitouli, Maria Palatianou, Angeliki Christidou, Nikolaos Dimitriadis, Andreas Nakos, Ploutarchos Pastras, Panagiotis Kourkoulis, Pantelis Karatzas, Miltiadis Moutzoukis, Charalampos Zlatinoudis, Athanasios Philippidis, Anastasia Kourikou, Georgios Kokkotis, Antonios Gklavas, Angeliki Machaira, Aikaterini Mantaka, Persefoni Talimtzi, Evaggelia Anagnostopoulou, Ioannis E. Koutroubakis, Ioannis Papaconstantinou, Georgios Bamias, Spilios Manolakopoulos, Nicoletta Mathou, Konstantina Paraskeva, Andreas Protopappas, Eftychia Tsironi, Konstantinos H. H. Katsanos, Dimitrios K. K. Christodoulou, Georgios Papatheodoridis, Georgios Michalopoulos, Georgios Theocharis, Christos Triantos, Ioannis Pachiadakis, Konstantinos Soufleris, Nikolaos Viazis, Gerassimos J. Mantzaris, Georgios Tribonias, Maria Tzouvala, Angeliki Theodoropoulou, Konstantinos Karmiris, Evanthia Zampeli, Spyridon Michopoulos, Anna-Bettina Haidich, Olga Giouleme
Summary: The aim of this study was to validate the content of IBD-Disk in a Greek cohort of IBD patients. The results showed good correlation and consistency between the scores of IBD-Disk and IBD-DI at baseline and follow-up. Female gender and extraintestinal manifestations were significantly associated with a higher IBD-Disk total score. Therefore, the Greek version of IBD-Disk was proven to be a reliable and valid tool for assessing IBD-related disability.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Rahma Elmahdi, Camilla E. Lemser, Sandra B. Thomsen, Kristine H. Allin, Manasi Agrawal, Tine Jess
Summary: This meta-analysis revealed that patients with pediatric-onset IBD have a more than 2-fold increased rate of cancer compared to the general pediatric population, primarily due to an increased rate of gastrointestinal cancers.
Review
Gastroenterology & Hepatology
Jee Hyun Kim, Chang-Myung Oh, Jun Hwan Yoo
Summary: Obesity is common in patients with inflammatory bowel disease (IBD), especially in newly developed countries. It has been suggested that 15%-40% of IBD patients are obese, and obesity may play a role in the development of IBD. Dysfunction of mesenteric fat can worsen the inflammation in Crohn's disease and lead to the formation of strictures or fistulas. Additionally, obesity can affect the course of the disease and the response to treatment in IBD. As a result, obesity control is being proposed as a novel management approach for IBD, and this review aims to discuss the impact of obesity on IBD treatment outcomes and the current status of pharmacologic or surgical anti-obesity treatments in IBD patients.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Gorm Roager Madsen, Kristina Bertl, Nikolaos Pandis, Andreas Stavropoulos, Johan Burisch
Summary: In this questionnaire-based study, periodontitis was found to be significantly associated with increased IBD disease activity in the last 12 months, as well as increased IBD disability.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Joana Torres, Catarina Gomes, Camilla Jensen, Manasi Agrawal, Francisco Morao, Tine Jess, Jean-Frederic Colombel, Kristine H. Allin, Johan Burisch
Summary: In this study, risk factors for unaffected first-degree relatives (FDRs) of inflammatory bowel disease (IBD) patients to develop the disease were identified. These findings provide an opportunity for counseling IBD relatives.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse
Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Medicine, General & Internal
Amanda Flanagan, Susan M. Allsopp, Sam A. O'Connor, Jacinta Tobin, Casper Pretorius, Ian S. Brown, Sally Bell, A. James M. Daveson
Summary: This study is the first to determine the incidence of IBD in Northern Australia and compare it with Southern Australia. The crude incidence rate of IBD in Australia is the highest reported. The findings suggest a possible correlation between the increased availability and early uptake of endoscopic procedures and the higher incidence of upper gastrointestinal Crohn's disease and complicated disease at diagnosis.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Hannah Gordon, Livia Biancone, Gionata Fiorino, Konstantinos H. Katsanos, Uri Kopylov, Eman Al Sulais, Jordan E. Axelrad, Karthiha Balendran, Johan Burisch, Lissy de Ridder, Lauranne Derikx, Pierre Ellul, Thomas Greuter, Marietta Iacucci, Caroline Di Jiang, Christina Kapizioni, Konstantinos Karmiris, Julien Kirchgesner, David Laharie, Triana Lobaton, Tamas Molnar, Nurulamin M. Noor, Rohit Rao, Simone Saibeni, Michael Scharl, Stephan R. Vavricka, Tim Raine
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Sigrun Grimsdottir, Mohamed Attauabi, Emilie Kristine Dahl, Johan Burisch, Jakob Benedict Seidelin
Summary: A systematic review found that a high proportion of patients with inflammatory bowel disease (IBD) experience flares following cancer treatment, with an increased risk of gastrointestinal toxicity in IBD patients receiving immune checkpoint inhibitor treatment. However, current studies suggest that IBD flares induced by cancer therapy can be managed and should not prevent appropriate cancer treatments.
JOURNAL OF CROHNS & COLITIS
(2023)
Editorial Material
Gastroenterology & Hepatology
Johan Burisch
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Editorial Material
Gastroenterology & Hepatology
Johan Burisch
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Uri Kopylov, Johan Burisch, Shomron Ben-Horin, Fiona Braegger, Alonso Fernandez-Nistal, Nuria Lara, Henriette Sophie Heinrich, Stephan R. Vavricka
Summary: This study demonstrated that vedolizumab treatment resulted in improvements in extraintestinal manifestations in patients with IBD, showing its effectiveness and good safety profile.
INFLAMMATORY BOWEL DISEASES
(2023)
Letter
Dermatology
Valdemar W. Nielsen, Astrid-Helene R. Jorgensen, Yiqiu Yao, Hans C. Ring, Mohamed Attauabi, Gorm R. Madsen, Johan Burisch, Simon F. Thomsen
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Johan Burisch, Ekaterina Safroneeva, Raphael Laoun, Christopher Ma
Summary: Although UC and CD share common pathways and treatments, CD patients are more likely to undergo surgery than UC patients. Early treatment in CD can modify the disease's natural history, but there is limited evidence supporting the utility of early escalation to advanced therapies in UC. More data is needed to determine the meaningfulness of different outcomes in UC and to analyze different populations of UC patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Hannah Gordon, Johan Burisch, Pierre Ellul, Konstantinos Karmiris, Konstantinos Katsanos, Mariangela Allocca, Giorgos Bamias, Manuel Barreiro-de Acosta, Tasanee Braithwaite, Thomas Greuter, Catherine Harwood, Pascal Juillerat, Triana Lobaton, Ulf Mueller-Ladner, Nurulamin Noor, Gianluca Pellino, Edoardo Savarino, Christoph Schramm, Alessandra Soriano, Juergen Michael Stein, Mathieu Uzzan, Patrick F. van Rheenen, Stephan R. Vavricka, Maurizio Vecchi, Stephane Zuily, Torsten Kucharzik
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Kristoffer Jarlov Jensen, Camilla Bjorn Jensen, Christina Wennerstroem, Johan Burisch, Janne Petersen
Summary: This study aimed to characterize the drug utilization and switch patterns of biological treatment for ulcerative colitis (UC) and Crohn's disease (CD). The majority of UC and CD patients initiating biologic therapy chose infliximab as their first-line treatment. Adalimumab had a higher risk of treatment discontinuation compared to infliximab, while vedolizumab had a lower risk of discontinuation for UC patients.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Medicine, General & Internal
Mohamed Attauabi, Emilie Kristine Dahl, Johan Burisch, John Gubatan, Ole Haagen Nielsen, Jakob Benedict Seidelin
Summary: This study compared the onset of efficacy of biological therapies and small molecules in patients with moderate-to-severe ulcerative colitis (UC). The results showed that upadacitinib had significantly better clinical response and clinical remission at two weeks compared to other agents, while ustekinumab and ozanimod had the lowest efficacy.
Article
Dentistry, Oral Surgery & Medicine
Kristina Bertl, Georgios Tsakos, Nikolaos Pandis, Anna Bogren, Johan Burisch, Andreas Stavropoulos
Summary: This study is the first to find that oral health problems are associated with the disease-specific quality of life (QoL) of inflammatory bowel disease (IBD) patients, and vice versa. This emphasizes the potential advantages of including dental professionals in the multi-disciplinary treatment teams of IBD patients.
JOURNAL OF CLINICAL PERIODONTOLOGY
(2023)